A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy
The purpose of this study is to determine the safety and acceptability of the experimental drug, AG-221, alone and in combination with azacitidine (Vidaza) that is approved by the US Food and Drug Administration (FDA) for MDS (myelodysplastic syndrome, a pre-leukemic condition) as well as a subset of AML subjects.
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-IDH2 mutation status
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 12 months of study drug treatment and 30 days after you stop taking the study drug.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Celgene